Corrigendum to “Cost of disorders of the brain in Europe 2010” [Eur. Neuropsychopharmacol. 21 (2011) 718–779]

Gustavsson, Anders; Svensson, Mikael; Jacobi, Frank; Allgulander, Christer; Alonso, Jordi; Beghi, Ettore; Dodel, Richard; Ekman, Mattias; Faravelli, Carlo; Fratiglioni, Laura; Gannon, Brenda; Jones, David Hilton; Jennum, Poul; Jordanova, Albena; Jönsson, Linus; Karampampa, Korinna; Knapp, Martín; Kobelt, Gisela; Kurth, Tobias; Lieb, Roselind; Linde, Mattias; Ljungcrantz, Christina; Maercker, Andreas; Melin, Beatrice; Moscarelli, Massimo; Musayev, Amir; Norwood, Fiona; Preisig, Martin; Pugliatti, Maura; Rehm, Jüergen; Salvador‐Carulla, Luis; Schlehofer, Brigitte; Simon, Roland; Steinhausen, Hans Christoph; Stovner, Lars Jacob; Vallat, Jean Michel; Bergh, Peter Van den; Os, Jim van; Vos, Pieter E.; Xu, Weili; Wittchen, H.‐U.; Olesen, Jes

doi:10.1016/j.euroneuro.2012.01.001

Cited by 19 publications

(23 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The synthesis of arylpiperazinylmethyl-dihydro [1,3]oxazolo [2,3-f]purinediones was accomplished as shown in Scheme 2. 8-Bromo-1,3-dimethyl-purine-2,6-dione reacted with the respective substituted oxiranes in the presence of a catalytic amount of pyridine in anhydrous 1-propanol.…”

Section: Chemistrymentioning

confidence: 99%

“…In comparison to the previously evaluated 8-alkoxy derivatives [15], we extended the length of the linker between purine-2,6-dione core and arylpiperazine fragment from four to five carbon units to check the influence of this modification on the receptor activity. Moreover, a series of LCAPs derivatives of dihydro [1,3]oxazolo[2,3-f]purinediones, which may be regarded as 8-methoxy-purine-2,6-dione analogs with methoxy group built into the cyclic oxygen ring system, were obtained. Herein, we report on their synthesis and evaluation for the selected serotoninergic (5-HT 1A , 5-HT 2A , 5-HT 6 , 5-HT 7 ) and dopaminergic (D 2 ) Rs as well as determination of their intrinsic activity for validation of the multireceptor approach.…”

Section: Introductionmentioning

confidence: 99%

“…A comprehensive study of mental disorders, based upon the international diagnostic classification system [1], which covers 19 major groups [2] revealed that neuropsychiatric illnesses represent a larger disease burden on society than either cardiovascular disease or cancer. Nowadays, the investment in research and development to create better psychotropic agents, especially for affective disorders (major depression, bipolar disorder) and schizophrenia, has declined [3,4].…”

Section: Introductionmentioning

confidence: 99%

“…

To obtain potential antidepressants and/or antipsychotics, a series of new long-chain arylpiperazine derivatives of 8-alkoxy-purine-2,6-dione (10-24) and dihydro [1,3] (15) showed a lack of activity in terms and under the conditions of the forced swim, four plate and amphetamineinduced hyperactivity tests in mice, probably as a result of its high first pass effect in the liver.

…”

mentioning

confidence: 99%

See 3 more Smart Citations

New Arylpiperazinylalkyl Derivatives of 8‐Alkoxy‐purine‐2,6‐dione and Dihydro[1,3]oxazolo[2,3‐f]purinedione Targeting the Serotonin 5‐HT_1A/5‐HT_2A/5‐HT₇ and Dopamine D₂ Receptors

Chłoń-Rzepa

Zagórska

Bucki

et al. 2015

Archiv der Pharmazie

View full text Add to dashboard Cite

To obtain potential antidepressants and/or antipsychotics, a series of new long-chain arylpiperazine derivatives of 8-alkoxy-purine-2,6-dione (10-24) and dihydro[1,3]oxazolo[2,3-f]purinedione (30-34) were synthesized and their serotonin (5-HT1A , 5-HT2A , 5-HT6 , 5-HT7 ) and dopamine (D2 ) receptor affinities were determined. The study allowed the identification of some potent 5-HT1A /5-HT7 /D2 ligands with moderate affinity for 5-HT2A sites. The binding mode of representative compounds from both chemical classes (11 and 31) in the site of 5-HT1A receptor was analyzed in computational studies. In functional in vitro studies, the selected compounds 15 and 16 showed antagonistic properties for the evaluated receptors. 8-Methoxy-7-{4-[4-(2-methoxyphenyl)-piperazin-1-yl]-butyl}-1,3-dimethyl-purine-2,6-dione (15) showed a lack of activity in terms and under the conditions of the forced swim, four plate and amphetamine-induced hyperactivity tests in mice, probably as a result of its high first pass effect in the liver.

show abstract

Section: Chemistrymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…

…”

mentioning

confidence: 99%

See 2 more Smart Citations

New Arylpiperazinylalkyl Derivatives of 8‐Alkoxy‐purine‐2,6‐dione and Dihydro[1,3]oxazolo[2,3‐f]purinedione Targeting the Serotonin 5‐HT_1A/5‐HT_2A/5‐HT₇ and Dopamine D₂ Receptors

Chłoń-Rzepa

Zagórska

Bucki

et al. 2015

Archiv der Pharmazie

View full text Add to dashboard Cite

show abstract

“…That's the conclusion of a report 1 commissioned by the European Brain Council that provides the most comprehensive assessment of the financial consequences of mental ailments so far.…”

mentioning

confidence: 99%

Trillion-dollar brain drain

Smith¹

2011

Nature

View full text Add to dashboard Cite

Identifying blood‐brain barrier peptides by using amino acids physicochemical properties and features fusion method

Zou

2021

Peptide Science

View full text Add to dashboard Cite

Blood-brain barrier peptides (BBPs) play a promising role in current drug study of central nervous system diseases. Hence, it is an urgent need to rapidly and accurately discriminating BBPs from non-BBPs. Experimental approaches are the first choice, however, these methods are expensive and take a lot of time. Thus, more and more researchers focused their attention on computational models. In current work, we developed a support vector machine (SVM) based model to identify BBPs. First, amino acids physicochemical properties were employed to represent peptide sequences, and Pearson's correlation coefficient (PCC) and maximal information coefficient (MIC) were applied to extract useful information. Then, similarity network fusion algorithm was utilized to integrate these two different kinds of features. Next, Fisher algorithm was used to pick out the discriminative features. Finally, these selected features were input into SVM for distinguishing BBPs from non-BBPs. The proposed model achieved 100.00% and 89.47% classification accuracies on training and independent datasets, respectively. Additionally, we found that pK2 (NH3) property of amino acid plays a key role in discriminating BBPs from non-BBPs. The results showed that our proposed method is effective, and achieved a significantly improvement in identifying BBPs, as compared with the state-of-the-art approach. The Matlab codes and datasets are freely available at https://figshare.com/articles/ online_resource/iBBPs_zip/14723766.blood-brain barrier peptides, MIC, PCC, similarity network fusion algorithm, support vector machine | INTRODUCTIONCurrently, central nervous system (CNS) diseases, such as Alzheimer's disease, [1,2] Parkinson's disease, [1,2] and brain tumor [3] are a serious threat to people's health. With the increasing of incidence of CNS diseases, more and more resource was devoted to study and treat CNS diseases.It is reported that CNS diseases account for about 25% of the burden of all diseases in high-income countries and Europe. [4] At present, the blood-brain barrier (BBB) is one of the key points in treatment of CNS diseases, which prevents drugs to arrive at their targets. [3,5] Fortunately, recent study found that some peptides have the ability to cross the BBB, these peptides were called as blood-brain barrier peptides (BBPs). [6] BBPs play an important role in CNS study and often show hormesis, [7] which provide a new idea to diagnose and treat brain diseases. Compared with conventional drugs, BBPs with the following advantages that are low immunogenicity and toxicity. [7,8] Hence, BBPs may be an ideal choice for the treatment of CNS diseases.Up to now, many efforts have been made in investigating BBPs, however, it is still a challenging task to identify BBPs. Experimental approaches are the first choice in BBPs identification, but these methods are expensive and take a lot of time, so researchers turned their attention to computational approaches. In fact, various computational models

show abstract

Corrigendum to “Cost of disorders of the brain in Europe 2010” [Eur. Neuropsychopharmacol. 21 (2011) 718–779]

Cited by 19 publications

References 0 publications

New Arylpiperazinylalkyl Derivatives of 8‐Alkoxy‐purine‐2,6‐dione and Dihydro[1,3]oxazolo[2,3‐f]purinedione Targeting the Serotonin 5‐HT_1A/5‐HT_2A/5‐HT₇ and Dopamine D₂ Receptors

New Arylpiperazinylalkyl Derivatives of 8‐Alkoxy‐purine‐2,6‐dione and Dihydro[1,3]oxazolo[2,3‐f]purinedione Targeting the Serotonin 5‐HT_1A/5‐HT_2A/5‐HT₇ and Dopamine D₂ Receptors

Trillion-dollar brain drain

Identifying blood‐brain barrier peptides by using amino acids physicochemical properties and features fusion method

Contact Info

Product

Resources

About

Corrigendum to “Cost of disorders of the brain in Europe 2010” [Eur. Neuropsychopharmacol. 21 (2011) 718–779]

Cited by 19 publications

References 0 publications

New Arylpiperazinylalkyl Derivatives of 8‐Alkoxy‐purine‐2,6‐dione and Dihydro[1,3]oxazolo[2,3‐f]purinedione Targeting the Serotonin 5‐HT1A/5‐HT2A/5‐HT7 and Dopamine D2 Receptors

New Arylpiperazinylalkyl Derivatives of 8‐Alkoxy‐purine‐2,6‐dione and Dihydro[1,3]oxazolo[2,3‐f]purinedione Targeting the Serotonin 5‐HT1A/5‐HT2A/5‐HT7 and Dopamine D2 Receptors

Trillion-dollar brain drain

Identifying blood‐brain barrier peptides by using amino acids physicochemical properties and features fusion method

Contact Info

Product

Resources

About

New Arylpiperazinylalkyl Derivatives of 8‐Alkoxy‐purine‐2,6‐dione and Dihydro[1,3]oxazolo[2,3‐f]purinedione Targeting the Serotonin 5‐HT_1A/5‐HT_2A/5‐HT₇ and Dopamine D₂ Receptors

New Arylpiperazinylalkyl Derivatives of 8‐Alkoxy‐purine‐2,6‐dione and Dihydro[1,3]oxazolo[2,3‐f]purinedione Targeting the Serotonin 5‐HT_1A/5‐HT_2A/5‐HT₇ and Dopamine D₂ Receptors